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Canine pluripotent stem cells: are
they ready for clinical applications?
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The derivation of canine embryonic stem cells and generation of canine-induced pluripotent stem cells are significant achievements that have unlocked the potential for developing novel cell-based disease models, drug discovery platforms, and transplantation
therapies in the dog. A progression from concept to cure in this clinically relevant companion animal will not only help our canine patients but also help advance human regenerative
medicine. Nevertheless, many issues remain to be resolved before pluripotent cells can
be used clinically in a safe and reproducible manner.
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Canine Embryonic Stem Cells
We were among a number of research groups between 2007 and 2009 who derived numerous canine
embryonic stem cell (cESC) lines from blastocyst stage embryos (1–6) (Table 1). These cESC lines
expressed the core pluripotency markers (Oct4, Sox2, and Nanog) and were capable of differentiating
into representative lineages of all three germ layers in vitro. Limited proliferative potential was
observed for several cESC lines tested by a few research groups (1, 2), while only the cESC lines
established by the Hough and Betts labs were capable of forming modest teratomas in vivo (4, 5).
Canine ESC colonies seem to exhibit two phenotypically discrete morphologies, with some
colonies having distinct borders and a flattened appearance similar to human ESCs (hESCs), whereas
others were three-dimensional, round, tightly packed colonies that resemble mouse ESCs (mESCs).
Interestingly, our mESC-like cESCs could not be successfully propagated long-term in KnockOut
serum (KSR)-containing medium supplemented with leukemia inhibitory factor (LIF) and basic
fibroblast growth factor (bFGF) (5), while the cESCs derived by Hayes et al. could not be cultured
long-term in medium containing LIF only, but formed loosely adhered colonies interspersed
with feeder cells (3). The hESC-like cESCs generated differed in growth factor dependency, as
prolonged maintenance required supplementation with either soley LIF or LIF and bFGF (4, 5).
Morphologically distinct cESC may represent multiple and perhaps metastable pluripotent states
(e.g., naïve and primed) that have been recently characterized for both mouse and human pluripotent
stem cells (PSCs) (7–9). It appears as though naïve and primed pluripotency may be at least partly
conserved within other Eutherian mammals because PSC lines with naïve-like characteristics have
been derived from rabbits (10), pigs (11), cows (12), and perhaps the dog (13). Many of these lines
must be established and/or maintained in the presence of LIF and inhibitors of glycogen synthase
kinase 3β and the MAP kinase pathway (2i), which suppress pro-differentiation stimuli (14). In
depth “omics” examination of the molecular signatures underlying cESCs and preimplantation dog
embryos will allow a greater understanding of the most relevant embryonic counterparts of differing
metastable pluripotent states and will help define and optimize specific culture conditions for their
unlimited self-renewal and directed differentiation into therapeutically desirable cell types.
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TABLE 1 | Summary of canine embryonic stem cells (cESCs) derived from dog embryos.
Reference

Derivation
method

Basal media

Growth
factors

Feeder
layers

In vitro
differentiation

In vivo
differentiation

Long-term
culture

(1)

Mechanical

DMEM/F12, 20% FBS

mLIF

MEFs
(mitomycin C)

By morphology

ND

Two cell lines,
eight passages

(2)

Explant

DMEM/F12, 15% FBS

hLIF

MEFs

Flow cytometry/RT-PCR

ND

One cell line, ND

(3)

Explant

DMEM/F12, 15% FBS

hLIF

MEFs
(γ-irradiation)

EB formation,
differentiation markers

Unsuccessful
NOD/SCID

One cell line,
>20 passages

(4)

Explant

DMEM/F12, 15% ESCqualified FBS or KSR

hLIF,
hbFGF

MEFs
(γ-irradiation)

EB formation, directed
differentiation

Teratomas
NOD/SCID

Four ESC lines,
>25 passages

(5, 6)

Explant and
immuno-dissection

KO-DMEM, 15% KSR

hLIF,
hbFGF

MEFs
(γ-irradiation)

EB formation, directed
diff. functional test

Limited teratomas
NOD/SCID

10+ cESC lines,
>37 passages

ND, not determined; KO, knockout; KSR, knockout serum replacement.

of reprograming factors is important for proper pluripotency
induction in the dog because most of the ciPSCs were generated
by retroviral transduction with human and murine homologous
sequences that remain expressed in late passage ciPSCs (22, 23,
27, 28). However, these retroviral methodologies are not favorable for prospective clinical transplantation therapies because of
their biased, non-random integration of transgenic sequences in
promoter and coding regions, which result in dysregulation of
endogenous gene expression leading to possible tumorigenesis
and/or immunogenicity problems (29, 30). Alternatively, nonintegrating reprograming systems have been developed and utilized in other species including episomal vectors, mini circle
DNAs, plasmid vectors, small molecules, mRNAs, recombinant
proteins, and transposons (31). Utilization of either the nonintegrating Sendai viral-based or Cre-excisable lentiviral-based
reprograming systems along with small molecular facilitators of
DNA demethylation on canine fibroblasts should facilitate the
generation of transgene integration-free iPS cells in the dog.

Canine-Induced Pluripotent Stem Cells
In 2006, Takahashi and Yamanaka (15) demonstrated that mouse
embryonic fibroblasts could be reprogramed to a pluripotent state
by the over-expression of exogenous pluripotency transcription
factors (Oct-4, Klf4, Sox2) and c-Myc (OKSM). These so-called
induced pluripotent cells (iPSCs) exhibit indefinite proliferative
capacity and were deemed pluripotent by the expression of ESCspecific genes and the formation of embryoid bodies and teratomas. It was also shown that they could contribute to chimeric
embryos with germline competency, demonstrating that iPSCs
and ESCs exhibit similar in vivo differentiation capabilities (16).
This initial publication has spurred a whole new research field
and subsequently iPSCs have now been generated in a number of
different mammals including the dog (17–19). However, random
infection and integration of viral transgenes introduces both population heterogeneity and asynchrony to iPSC generation. Presumptive iPSC clones should be extensively screened with surface
markers that best correlate with active endogenous pluripotency
circuitry (20, 21). Unfortunately, there are discrepancies with
regards to the antigen profile of ciPSCs and not all laboratories
have access to canine embryos to properly control for antibody
specificity (22–24). To date, there have been seven reports on the
production of canine (c)iPSCs (Table 2). Two studies reprogramed
canine embryonic fibroblasts (23, 25), while three used adult skin
fibroblasts of various ages as the source of parental cells (22,
26, 27) by either retro- or lentiviral transduction of dog (25),
human (23, 26, 27), or mouse (22) pluripotency transcription
factor homologs. Two studies reported the generation of ciPSCs
from adipose multipotent stromal cells (24, 26), whereas the
Cibelli laboratory reprogramed from testicular fibroblasts (28).
The ability to reprogram cells from multiple tissues accessible
during routine procedures minimizes unnecessary harm to the
patient, but it is currently unknown why different somatic cell
types achieve dissimilar reprograming efficiencies (26).
Like their cESC counterparts, the majority of generated ciPSCs
favor dual-factor culture of both bFGF and LIF for proliferation
in the undifferentiated state (22–26, 28), but with only a few
reports of in vivo teratoma formation (22, 26). A LIF-dependent
ciPSC line was established using the standard “Yamanaka” factors
(OCT4, KLF4, SOX2, and c-MYC) plus LIN28 and NANOG, however germ cell-like tumors were formed upon engraftment into
NOD/SCID mice (27). It is presently unclear if species-specificity
Frontiers in Veterinary Science | www.frontiersin.org

Considerations for Clinical Translation of
Canine Pluripotent Stem Cell Technologies
The generation of canine pluripotent stem cells (cPSC) with
disease-specific alleles and the derivation of cell types afflicted
by the disease promises the development of novel cellular disease models, drug screening platforms, and potential regenerative
therapies. It seems that cPSC technologies may be on the verge
of clinical translation in the dog (6, 23, 26, 32), however to
facilitate these cPSC-based treatments a number of hurdles need
to be overcome. Canine iPSC generation efficiencies have not
been routinely included in publications, but have been reported
as low as 7.0 × 10−4 % (27). This poses a fundamental question
regarding the optimal trophic and physicochemical requirements
of cPSCs. To date, we are unsure of how or when key signaling
pathways are critical for the growth and epigenetic resetting of
transduced canine cells. Despite of this fact, two canine somatic
cell reprograming protocols have applied the transforming growth
factor β (TGFβ) receptor inhibitor A-83-01 (25, 27), presumably
to facilitate epithelialization of transduced cells.
Current differentiation strategies for PSCs produce cell types
that correspond to immature, but lineage-committed cells from
embryonic or fetal sources. Subsequently, PSC derivatives are
matured with sequential growth factor exposure within a
2
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TABLE 2 | Summary of canine induced pluripotent stem cells (ciPSCs) generated from dog cells.
Reference

Cell
sources

Basal media

Media
supplements

Feeder
layers

In vitro
differentiation

In vivo
differentiation

Reprogram
method

(25)

Embryonic fibroblasts

Primate ES medium

bFGF,
hLIF + 3i VPA

MEFs

In vitro differentiation

ND

Retrovirus
(canine OKSM)

(28)

Testicular fibroblasts

DMEM/F12, 15%
KSR

bFGF, hLIF

MEFs

Embryoid bodies

No teratoma
formation

Lentivirus
(human OKSM)

(26)

Adipose stromal
cells, skin fibroblasts

KO-DMEM, 20%
ES qualified FBS

bFGF, hLIF

MEFs

Embryoid bodies

Teratomas

Lentivirus
(human OKSM)

(27)

Dermal fibroblasts

KO-DMEM/F12,
20% KSR

mLIF

MEFs

ND

Germ cell-like
tumor

Lentivirus
(human OKSMLN)

(22)

Skin fibroblasts

DMEM/F12, 20%
KSR

bFGF,
hLIF + 2i

MEFs

Embryoid bodies

Teratomas

Retrovirus
(mouse OKSM)

(23)

Embryonic fibroblasts

DMEM/F12, 20%
KSR

bFGF, hLIF

MEFs

Embryoid bodies, platelets

ND

Lentivirus
(human OKSM)

(24)

Ad-MSCs

DMEM/F12, 15%
FCS

bFGF, LIF

MEFs

Spontaneous differentiation,
embryoid bodies

ND

Retroviral
(human OKSM)

ND, not determined; OKSM, OCT4, KLF4, SOX2, and c-MYC transgenes; LN, LIN28, NANOG transgenes.

microenvironmental niche that favors the desired cell type (33).
We have established synaptically competent neurons from cESCs,
but were only functional when co-cultured with primary neurons derived from canine fetuses (6). Nishimura and colleagues
differentiated ciPSCs into mature megakaryocytes that released
functional platelets in vitro (23), while Deanne Whitworth has
recently derived highly proliferative mesenchymal stromal cells
(MSCs) from ciPSCs that undergo robust differentiation into the
osteo-, chondro- and adipogenic cell lineages (32). Excitingly,
Joseph Wu’s group at Stanford has demonstrated the preclinical
potential of ciPSCs by treating immunodeficient mouse models
of myocardial infarction and hindlimb ischemia with transplanted
endothelial cells derived from ciPSCs (26).
All cPSC lines have been established and differentiated in culture systems that expose the canine cells to proteins or feeder
cells from another species. Xeno-contamination is an important
biosafety concern for graft recipients and can be limited if chemically defined culture media (i.e., serum free with recombinant factors) can be adapted for the derivation and maintenance of cPSCs
(34). Moreover, technologies that enable the characterization of
desired cell fates in individual cells (e.g., flow-based quantification
of marker expression, RNA-sequencing, chromatin state, etc.) and
the production of highly purified cell types with adult-like functional properties in vivo (e.g., small molecule inhibitors/activators
of signaling pathways, three-dimensional scaffolds, etc.) need to
be further developed (33).
Combining patient-specific ciPSC generation with targeted
genome editing technologies (35) will enable correction of genetic
defects, thereby offering potential treatment of some inherited
canine diseases (36). Initially, genome editing will allow for the
genetic alteration of existing cESC lines or gene correction of
ciPSC lines that have been reprogramed from diseased canine cells
to produce isogenic comparisons that can be utilized for disease
modeling. In the long term, diseased and allele-corrected ciPSCs
will serve as provocative tools within pharmacological screening
platforms for efficient and predictive drug discovery and toxicity
studies for the treatment of various diseases in the dog (36, 37).
It is anticipated over the next few years that the CRISPR/Cas9
genome editing system will be rapidly implemented as a means to
Frontiers in Veterinary Science | www.frontiersin.org

conduct loss-of-function gene mutation studies in cESCs and/or
to correct genetic mutations in ciPSCs generated from fibroblasts
with a disease-causing allele, as a proof of principle study.
Realizing the therapeutic potential of PSCs for clinical applications remain a central goal for the veterinary and scientific
communities. Since at least half of all heritable canine diseases are
known to have human equivalents (38), the dog will increasingly
become an unrivaled translational animal model for developing
stem cell-based therapies in humans as well. Thus, key components for any successful cPSC-based treatment will be the ability
to efficiently produce ciPSCs without off-target genetic alterations
or karyotypic abnormalities (39), to produce a pure population
of cPSC derivatives in a scalable and good manufacturing practice (GMP)-cooperative manner, and the selection of appropriate
diseases to target for regenerative medicine in the dog (33, 36).
The relatively relaxed legal and ethical regulation of veterinary
stem cell research compared to human medicine has facilitated
the development and clinical application of a number of unproven
cell-based therapies in large animals including the dog (40). The
Food and Drug Administration (FDA) recently issued a draft
guidance for industry on cell-based products for animal use (Draft
Guidance #218) that clarifies how existing FDA regulations apply
to cell-based products and encourages stakeholders to communicate and interact with the FDA early in the developmental process
for each stem cell product. These guidelines and future FDA
regulations of veterinary stem cell-based therapies may spearhead
the much-needed double-blinded, randomized, and controlled
clinical trials to properly evaluate the safety, utility, and efficacy
of cPSC-based therapies in the dog.
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